In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

Abbott India continued to benefit from anti-infectives and medications for gastrointestinal conditions, the company said ...

Glaxo (GSK) delivered earnings and revenue surprises of 9.48% and 2.16%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

GSK lands on Morningstar’s Best Companies to Own list for 2024. It’s also one of ... Additionally, GSK has developed next-generation drugs in respiratory and HIV that should help mitigate ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... our antibody drug conjugate for extensive stage small-cell lung cancer.

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Oct 29 (Reuters) - India's GlaxoSmithKline Pharmaceuticals ... pricing curbs on some of its drugs that were added to the Indian government's essential medicines list (NLEM) since September ...